Disc Medicine, Inc. IRON
76.11 USD -1.87 (-2.40%)
Regular-session close
76.11 0.00 0.00%
After hours · Nov 19, 4:26 PM ET
75.98 Day range 78.90
40.00 52-week range 99.50
- YTD
- -4.16%
- 1 year
- -16.12%
News
benzinga.com Cantor Fitzgerald Reiterates Overweight on Disc Medicine, Maintains $170 Price Target Cantor Fitzgerald analyst Kristen Kluska reiterates Disc Medicine (NASDAQ:IRON) with a Overweight and maintains $170 price target.
benzinga.com Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $104 Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $92 to $104.
seekingalpha.com Disc Medicine, Inc. (IRON) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript Disc Medicine, Inc. (IRON) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
defenseworld.net Disc Medicine, Inc. $IRON Holdings Raised by Alps Advisors Inc. Alps Advisors Inc. lifted its position in shares of Disc Medicine, Inc. (NASDAQ: IRON) by 31.9% during the third quarter, according to its most recent filing with the Securities and Exchange…benzinga.com Guggenheim Initiates Coverage On Disc Medicine with Buy Rating, Announces Price Target of $132 Guggenheim analyst Debjit Chattopadhyay initiates coverage on Disc Medicine (NASDAQ:IRON) with a Buy rating and announces Price Target of $132.
benzinga.com HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $127 HC Wainwright & Co. analyst Douglas Tsao maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $120 to $127.
benzinga.com Disc Medicine Q3 EPS $(1.53) Beats $(1.76) Estimate Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.53) per share which beat the analyst consensus estimate of $(1.76) by 13.07 percent. This is a 13.56 percent increase over losses of…
globenewswire.com Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel…
globenewswire.com Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting WATERTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel…
globenewswire.com Disc Medicine to Participate in Upcoming Investor Conferences WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel…
globenewswire.com Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization…benzinga.com Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $92 Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $90 to $92.
benzinga.com Truist Securities Maintains Buy on Disc Medicine, Raises Price Target to $115 Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $83 to $115.
benzinga.com Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $124 Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $86 to $124.
benzinga.com Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $110 Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $100 to $110.
benzinga.com Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.
globenewswire.com Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization…
seekingalpha.com Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcript Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcript
benzinga.com Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 300 points on Monday.The Dow traded up 0.06% to 52,031.59 while the NASDAQ jumped 1.24% to 26,465.39.…benzinga.com BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120 BMO Capital analyst Evan David Seigerman maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $100 to $120.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX)…
benzinga.com Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study Disc Medicine Inc. (NASDAQ:IRON) on Monday reported positive topline results from its APOLLO Phase 3 trial evaluating bitopertin for erythropoietic protoporphyria, or EPP, including X-linked…
benzinga.com Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study Disc Medicine reports positive Phase 3 results for bitopertin in EPP, meeting all primary and secondary endpoints. NDA resubmission planned.
invezz.com Disc Medicine stock soars: take profit or buy into strength? Disc Medicine (IRON) shares ripped higher on Monday morning after the company's experimental blood-disorder treatment, bitopertin, delivered positive Phase 3 results. In its press release, management…
gurufocus.com Disc Medicine (IRON) Achieves Positive Phase 3 Trial Results for EPP Treatment Disc Medicine (IRON) is experiencing a significant surge today following the announcement of positive results from its pivotal Phase 3 APOLLO trial for bitopert
marketbeat.com Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission Disc Medicine NASDAQ: IRON said its Phase III APOLLO trial of investigational bitopertin met both co-primary endpoints and all secondary endpoints in patients with erythropoietic protoporphyria (EPP)…
barrons.com Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes Disc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-stage trial met all its primary and secondary goals.
proactiveinvestors.com Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints Disc Medicine (NASDAQ:IRON), the clinical-stage biopharmaceutical company, surged 38% to $78.24 on Monday after its experimental drug bitopertin met every endpoint in a pivotal phase 3 trial. The…benzinga.com Cantor Fitzgerald Maintains Overweight on Disc Medicine, Raises Price Target to $170 Cantor Fitzgerald analyst Kristen Kluska maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $125 to $170.
benzinga.com Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday U.S. stocks mixed as Dow fell ~100 points; Silence Therapeutics surged 125.7% on Merck KGaA buyout, while biotech and tech shares gained.
benzinga.com Stock Market Today: Dow Futures Drop, S&P 500, Nasdaq 100 Rise as Scott Bessent Links September Inflation to 'Energy Shock'— RCAT, ESLT, STLD in Focus (UPDATED) U.S. stock futures were higher on Monday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Friday's lower close.
reuters.com Disc Medicine's rare disease drug succeeds in late-stage trial Disc Medicine's rare disease drug succeeds in late-stage trial
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved…
globenewswire.com Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP) Positive APOLLO trial topline results demonstrated statistically significant and clinically meaningful benefit across all study endpoints Successfully met co-primary endpoints of reduction in…
benzinga.com Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket XCF Global surged 64.9% premarket after completing a business combination and forecasting 2025 revenue of $120M-$130M and EBITDA of $70M-$75M.
globenewswire.com Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP) WATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel…
feeds.newsfilecorp.com ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON New York, New York--(Newsfile Corp. - October 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm,
newsfilecorp.com ROSEN, LEADING INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON New York, New York--(Newsfile Corp. - October 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc…
globenewswire.com Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine,…
